Without ensuring Payers, Patients and Prescribers receive cohesive and consistent messaging, patients will not gain access to innovative drugs, and pharma won’t be reimbursed. A truly multi-stakeholder approach needs to form the basis of commercial models.
In eyeforpharma’s latest white paper, “Balancing payers, patients and physicians: An integrated multi-stakeholder approach” Actelion, Pfizer, Bayer, Otsuka Pharmaceuticals, VClinBio and Salesforce share radical changes made to their organisational structure, which integrates their new approaches towards stakeholders.
The white paper, details:
• The shift of HCP’s from administrators of medicine to collaborators in patients care, and how pharma have changed engagement accordingly.
• How economic pressures have effected payer demands – giving them more clout in patient access.
• How to adapt outdated commercial models to enhance cross-functionality
Download this white paper here and see how to overcome the challenges of the new multi-stakeholder model, a revolution is not required.
I hope you find this content useful.
This email advertisement was sent on behalf of eyeforpharma by HealthEconomics.Com, 449 S. Mill View Way, Ponte Vedra Beach, FL 32082.